Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731020 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTNPC1DGAT2CYP11B2 | |
| SCHEMBL30731000 | 0.81 | MEN1 (0.40) | SMN1; SMN2MAPTNPC1CYP11B2HTT | |
| SCHEMBL22554028 | 0.81 | MEN1 (0.40) | SMN1; SMN2MAPTNPC1CYP11B2HTT | |
| SCHEMBL30730847 | 0.76 | PIP4K2A (0.40) | NPC1CYP11B2HPGDSALDH1A1CYP11B1 | |
| SCHEMBL22553771 | 0.76 | PIP4K2A (0.40) | NPC1CYP11B2HPGDSALDH1A1CYP11B1 | |
| SCHEMBL22553938 | 0.75 | NUDT1 (0.43) | SMN1; SMN2MAPTNPC1DGAT2CYP11B2 | |
| SCHEMBL30731117 | 0.75 | NUDT1 (0.43) | SMN1; SMN2MAPTNPC1DGAT2CYP11B2 | |
| SCHEMBL30730826 | 0.75 | NUDT1 (0.43) | SMN1; SMN2MAPTNPC1DGAT2CYP11B2 | |
| SCHEMBL22553750 | 0.75 | CYP11B2 (0.39) | SMN1; SMN2NPC1CYP11B2HTTALDH1A1 | |
| SCHEMBL22554276 | 0.75 | DGAT2 (0.40) | SMN1; SMN2MAPTNPC1DGAT2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | claimed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | SMN1; SMN2 3679/4885MAPT 1003/4885NPC1 1648/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | SMN1; SMN2 3679/4885MAPT 1003/4885NPC1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.